NO301311B1 - Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser - Google Patents

Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser Download PDF

Info

Publication number: NO301311B1
Authority: NO; Norway
Prior art keywords: carbon atoms; alcohol; amperozide; hydrogen; abuse
Prior art date: 1991-03-22

Application number

NO924502A

Other languages

English (en)

Norwegian (no)

Other versions

NO924502D0 (no

NO924502L (no

Inventor

Anders Bjoerk

Erik Christensson

Original Assignee

Pharmacia Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-22

Filing date

1992-11-23

Publication date

1997-10-13

1992-11-23 Application filed by Pharmacia Ab filed Critical Pharmacia Ab

1992-11-23 Publication of NO924502D0 publication Critical patent/NO924502D0/no

1992-11-23 Publication of NO924502L publication Critical patent/NO924502L/no

1997-10-13 Publication of NO301311B1 publication Critical patent/NO301311B1/no

Links

PTPTUSSTCDZDGG-UHFFFAOYSA-N 2-(4,4-diphenylbutyl)piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1CCCC(C=1C=CC=CC=1)C1=CC=CC=C1 PTPTUSSTCDZDGG-UHFFFAOYSA-N 0.000 title claims abstract description 7
201000009032 substance abuse Diseases 0.000 title description 25
238000011282 treatment Methods 0.000 title description 18
208000011117 substance-related disease Diseases 0.000 title description 16
231100000736 substance abuse Toxicity 0.000 title description 9
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 6
NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 claims abstract description 35
239000003814 drug Substances 0.000 claims abstract description 33
230000000631 nonopiate Effects 0.000 claims abstract description 14
208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims abstract description 7
206010048010 Withdrawal syndrome Diseases 0.000 claims abstract description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 68
ZPUCINDJVBIVPJ-LJISPDSOSA-N ***e Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 34
239000000126 substance Substances 0.000 claims description 21
229960003920 ***e Drugs 0.000 claims description 17
125000004432 carbon atom Chemical group C* 0.000 claims description 16
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
229960002715 nicotine Drugs 0.000 claims description 10
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 8
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 6
150000002367 halogens Chemical class 0.000 claims description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 6
125000003545 alkoxy group Chemical group 0.000 claims description 4
229910052794 bromium Inorganic materials 0.000 claims description 4
229910052801 chlorine Inorganic materials 0.000 claims description 4
229910052731 fluorine Inorganic materials 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
125000003342 alkenyl group Chemical group 0.000 claims description 2
150000001412 amines Chemical class 0.000 claims description 2
125000003710 aryl alkyl group Chemical group 0.000 claims description 2
229910021398 atomic carbon Inorganic materials 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
150000002431 hydrogen Chemical group 0.000 claims description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
229910052760 oxygen Inorganic materials 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
229940079593 drug Drugs 0.000 abstract description 32
229950000388 amperozide Drugs 0.000 abstract description 31
206010012335 Dependence Diseases 0.000 abstract description 6
230000001629 suppression Effects 0.000 abstract description 3
230000002265 prevention Effects 0.000 abstract description 2
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
230000000694 effects Effects 0.000 description 16
150000001875 compounds Chemical class 0.000 description 12
241000700159 Rattus Species 0.000 description 11
229960004756 ethanol Drugs 0.000 description 10
206010013663 drug dependence Diseases 0.000 description 9
229960003638 dopamine Drugs 0.000 description 8
230000035622 drinking Effects 0.000 description 8
230000006399 behavior Effects 0.000 description 6
230000037396 body weight Effects 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
210000004556 brain Anatomy 0.000 description 5
208000035475 disorder Diseases 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000000203 mixture Substances 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
229960002073 sertraline Drugs 0.000 description 5
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 5
230000002747 voluntary effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
230000009471 action Effects 0.000 description 4
238000010171 animal model Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
230000003533 narcotic effect Effects 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
230000002787 reinforcement Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
208000022497 Cocaine-Related disease Diseases 0.000 description 3
XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 3
239000002981 blocking agent Substances 0.000 description 3
230000007423 decrease Effects 0.000 description 3
239000002858 neurotransmitter agent Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000000697 serotonin reuptake Effects 0.000 description 3
230000013275 serotonin uptake Effects 0.000 description 3
208000007848 Alcoholism Diseases 0.000 description 2
206010013654 Drug abuse Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
230000003542 behavioural effect Effects 0.000 description 2
229940049706 benzodiazepine Drugs 0.000 description 2
150000001557 benzodiazepines Chemical class 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
201000006145 ***e dependence Diseases 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
230000008918 emotional behaviour Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000002197 limbic effect Effects 0.000 description 2
210000003715 limbic system Anatomy 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000010534 mechanism of action Effects 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
229950010883 phencyclidine Drugs 0.000 description 2
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000862 serotonergic effect Effects 0.000 description 2
229940076279 serotonin Drugs 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 2
229960002791 zimeldine Drugs 0.000 description 2
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
102000004300 GABA-A Receptors Human genes 0.000 description 1
108090000839 GABA-A Receptors Proteins 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
206010043903 Tobacco abuse Diseases 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
206010001584 alcohol abuse Diseases 0.000 description 1
208000025746 alcohol use disease Diseases 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960001653 citalopram Drugs 0.000 description 1
201000001272 ***e abuse Diseases 0.000 description 1
238000011284 combination treatment Methods 0.000 description 1
235000019788 craving Nutrition 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
229960003529 diazepam Drugs 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000037406 food intake Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
230000035873 hypermotility Effects 0.000 description 1
BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
229960004801 imipramine Drugs 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
229940126601 medicinal product Drugs 0.000 description 1
230000036651 mood Effects 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000003149 muscarinic antagonist Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000001009 nucleus accumben Anatomy 0.000 description 1
229940127240 opiate Drugs 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001242 postsynaptic effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
230000007593 synaptic transmission, glutaminergic Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
230000036642 wellbeing Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Addiction (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO924502A 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser NO301311B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9100860A SE9100860D0 (sv)	1991-03-22	1991-03-22	New use
PCT/SE1992/000182 WO1992016211A1 (en)	1991-03-22	1992-03-23	New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (3)

Publication Number	Publication Date
NO924502D0 NO924502D0 (no)	1992-11-23
NO924502L NO924502L (no)	1992-11-23
NO301311B1 true NO301311B1 (no)	1997-10-13

Family

ID=20382242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO924502A NO301311B1 (no)	1991-03-22	1992-11-23	Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Country Status (24)

Country	Link
US (2)	US5434156A (ro)
EP (1)	EP0538422B1 (ro)
JP (1)	JP3221611B2 (ro)
KR (1)	KR100196674B1 (ro)
AT (1)	ATE199057T1 (ro)
AU (1)	AU653797B2 (ro)
BG (1)	BG61829B1 (ro)
BR (1)	BR9204969A (ro)
CA (1)	CA2083505C (ro)
CZ (1)	CZ282222B6 (ro)
DE (1)	DE69231680T2 (ro)
DK (1)	DK0538422T3 (ro)
EE (1)	EE02973B1 (ro)
ES (1)	ES2154261T3 (ro)
GR (1)	GR3035805T3 (ro)
HU (2)	HU9203632D0 (ro)
IE (1)	IE920920A1 (ro)
NO (1)	NO301311B1 (ro)
PT (1)	PT100279B (ro)
RO (1)	RO109702B1 (ro)
RU (1)	RU2095062C1 (ro)
SE (1)	SE9100860D0 (ro)
SK (1)	SK279237B6 (ro)
WO (1)	WO1992016211A1 (ro)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9100860D0 (sv) *	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use
SE9201239D0 (sv) *	1992-04-21	1992-04-21	Kabi Pharmacia Ab	Agents for treating substance abuse disorders
JP3571114B2 (ja) *	1995-07-11	2004-09-29	ポーラ化成工業株式会社	麻薬拮抗剤
US6265393B1 (en)	1998-08-07	2001-07-24	Heinrichs William Leroy	Prevention of endometriosis signs or symptons
US6090780A (en) *	1999-04-07	2000-07-18	Chandon Prasad	Histidyl-proline diketopiperazine and method of use
GB9923748D0 (en)	1999-10-07	1999-12-08	Glaxo Group Ltd	Chemical compounds
USRE39921E1 (en)	1999-10-07	2007-11-13	Smithkline Beecham Corporation	Chemical compounds
GB0025354D0 (en)	2000-10-17	2000-11-29	Glaxo Group Ltd	Chemical compounds
NZ527583A (en) *	2001-01-17	2006-03-31	Hythiam Inc	Use of flumazenil in developing a drug for the treatment of alcohol dependence
US20050192271A1 (en) *	2003-07-15	2005-09-01	Hythiam, Inc.	Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US7183410B2 (en) *	2001-08-02	2007-02-27	Bidachem S.P.A.	Stable polymorph of flibanserin
US20030060475A1 (en) *	2001-08-10	2003-03-27	Boehringer Ingelheim Pharma Kg	Method of using flibanserin for neuroprotection
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
GB0203022D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
GB0203020D0 (en)	2002-02-08	2002-03-27	Glaxo Group Ltd	Chemical compounds
EP1472222A1 (en)	2002-02-08	2004-11-03	Glaxo Group Limited	Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
RU2445095C2 (ru) *	2004-04-22	2012-03-20	Бёрингер Ингельхайм Интернациональ Гмбх	Новые фармацевтические композиции для лечения сексуальных расстройств
US20050239798A1 (en) *	2004-04-22	2005-10-27	Boehringer Ingelheim Pharmaceuticals, Inc.	Method for the treatment of premenstrual and other female sexual disorders
US20060025420A1 (en) *	2004-07-30	2006-02-02	Boehringer Ingelheimn International GmbH	Pharmaceutical compositions for the treatment of female sexual disorders
CA2576812A1 (en) *	2004-09-03	2006-03-09	Boehringer Ingelheim International Gmbh	Method for the treatment of attention deficit hyperactivity disorder
EP1858516A1 (en) *	2005-03-04	2007-11-28	Boehringer Ingelheim International GmbH	Pharmaceutical compositions for the treatment and/or prevention of depression
US20060199805A1 (en) *	2005-03-04	2006-09-07	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
WO2006096439A2 (en) *	2005-03-04	2006-09-14	Boehringer Ingelheim International Gmbh	Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
EP1904182A2 (en) *	2005-05-06	2008-04-02	Boehringer Ingelheim International GmbH	Method for the treatment of drug abuse with flibanserin
EP1888071A1 (en) *	2005-05-19	2008-02-20	Boehringer Ingelheim International GmbH	Method for the treatment of drug-induced sexual dysfunction
EP1888070A1 (en) *	2005-05-19	2008-02-20	Boehringer Ingelheim International GmbH	Method for the treatment of sexual dysfunctions due to medical conditions
US8227476B2 (en)	2005-08-03	2012-07-24	Sprout Pharmaceuticals, Inc.	Use of flibanserin in the treatment of obesity
US7923449B2 (en) *	2005-10-29	2011-04-12	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070123540A1 (en) *	2005-10-29	2007-05-31	Angelo Ceci	Sexual desire enhancing medicaments comprising benzimidazolone derivatives
US20070105869A1 (en) *	2005-11-08	2007-05-10	Stephane Pollentier	Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
AU2007247094B2 (en) *	2006-05-09	2012-11-01	Sprout Pharmaceuticals, Inc.	Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders
CA2654798C (en)	2006-06-30	2015-01-13	Boehringer Ingelheim International Gmbh	Flibanserin for the treatment of urinary incontinence and related diseases
EP2043648A1 (en) *	2006-07-14	2009-04-08	Boehringer Ingelheim International GmbH	Use of flibanserin for the treatment of sexual disorders in females
CL2007002214A1 (es) *	2006-08-14	2008-03-07	Boehringer Ingelheim Int	Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
AU2007286288A1 (en)	2006-08-14	2008-02-21	Boehringer Ingelheim International Gmbh	Formulations of flibanserin and method for manufacturing the same
WO2008022932A2 (en) *	2006-08-25	2008-02-28	Boehringer Ingelheim International Gmbh	Controlled release system and method for manufacturing the same
UY31335A1 (es)	2007-09-12	2009-04-30		Tratamiento de sintomas vasomotores

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NO154582C (no) *	1978-10-20	1986-11-05	Ferrosan Ab	Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) *	1991-03-22	1991-03-22	Kabi Pharmacia Ab	New use

1991
- 1991-03-22 SE SE9100860A patent/SE9100860D0/xx unknown
1992
- 1992-03-23 EP EP92907159A patent/EP0538422B1/en not_active Expired - Lifetime
- 1992-03-23 US US07/949,869 patent/US5434156A/en not_active Expired - Fee Related
- 1992-03-23 JP JP50658392A patent/JP3221611B2/ja not_active Expired - Fee Related
- 1992-03-23 SK SK3449-92A patent/SK279237B6/sk unknown
- 1992-03-23 IE IE092092A patent/IE920920A1/en not_active IP Right Cessation
- 1992-03-23 CZ CS923449A patent/CZ282222B6/cs not_active IP Right Cessation
- 1992-03-23 RO RO92-01457A patent/RO109702B1/ro unknown
- 1992-03-23 HU HU9203632A patent/HU9203632D0/hu unknown
- 1992-03-23 ES ES92907159T patent/ES2154261T3/es not_active Expired - Lifetime
- 1992-03-23 CA CA002083505A patent/CA2083505C/en not_active Expired - Fee Related
- 1992-03-23 WO PCT/SE1992/000182 patent/WO1992016211A1/en active IP Right Grant
- 1992-03-23 RU RU9292016400A patent/RU2095062C1/ru not_active IP Right Cessation
- 1992-03-23 DK DK92907159T patent/DK0538422T3/da active
- 1992-03-23 AT AT92907159T patent/ATE199057T1/de not_active IP Right Cessation
- 1992-03-23 KR KR1019920702939A patent/KR100196674B1/ko not_active IP Right Cessation
- 1992-03-23 PT PT100279A patent/PT100279B/pt not_active IP Right Cessation
- 1992-03-23 BR BR9204969A patent/BR9204969A/pt not_active Application Discontinuation
- 1992-03-23 AU AU14280/92A patent/AU653797B2/en not_active Ceased
- 1992-03-23 HU HU9203632A patent/HU217833B/hu not_active IP Right Cessation
- 1992-03-23 DE DE69231680T patent/DE69231680T2/de not_active Expired - Fee Related
- 1992-11-20 BG BG97108A patent/BG61829B1/bg unknown
- 1992-11-23 NO NO924502A patent/NO301311B1/no unknown
1994
- 1994-11-17 EE EE9400358A patent/EE02973B1/xx not_active IP Right Cessation
1995
- 1995-04-25 US US08/428,899 patent/US5618817A/en not_active Expired - Fee Related
2001
- 2001-04-27 GR GR20010400653T patent/GR3035805T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69231680D1 (de)	2001-03-15
RU2095062C1 (ru)	1997-11-10
KR100196674B1 (ko)	1999-06-15
HU9203632D0 (en)	1993-03-29
JPH05507731A (ja)	1993-11-04
ATE199057T1 (de)	2001-02-15
BG61829B1 (bg)	1998-07-31
SE9100860D0 (sv)	1991-03-22
BR9204969A (pt)	1993-07-27
EP0538422B1 (en)	2001-02-07
DE69231680T2 (de)	2001-06-07
ES2154261T3 (es)	2001-04-01
KR930700108A (ko)	1993-03-13
AU1428092A (en)	1992-10-21
HUT64696A (en)	1994-02-28
DK0538422T3 (da)	2001-05-07
EE02973B1 (et)	1997-04-15
SK279237B6 (sk)	1998-08-05
SK344992A3 (en)	1995-11-08
CA2083505C (en)	2003-06-10
AU653797B2 (en)	1994-10-13
PT100279B (pt)	1999-06-30
CA2083505A1 (en)	1992-09-23
PT100279A (pt)	1993-07-30
HU217833B (hu)	2000-04-28
IE920920A1 (en)	1992-09-23
US5434156A (en)	1995-07-18
EP0538422A1 (en)	1993-04-28
JP3221611B2 (ja)	2001-10-22
GR3035805T3 (en)	2001-07-31
NO924502D0 (no)	1992-11-23
NO924502L (no)	1992-11-23
BG97108A (bg)	1994-03-24
CZ282222B6 (cs)	1997-06-11
RO109702B1 (ro)	1995-05-30
CZ344992A3 (en)	1994-02-16
US5618817A (en)	1997-04-08
WO1992016211A1 (en)	1992-10-01

Publication	Publication Date	Title
NO301311B1 (no)	1997-10-13	Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser
Carroll et al.	1990	Fluoxetine reduces intravenous ***e self-administration in rats
IE83379B1 (en)		New use of diphenylbutylpiperazinecarboxamides in the treatment of substance abuse
EP0637242B1 (en)	1999-09-15	Agents for treating substance abuse disorders
EP0900082B1 (en)	2001-11-07	Use of pyridyl- and pyrimidyl-piperazines for the manufacture of a medicament for the treatment of substance abuse disorders
WO2010151258A1 (en)	2010-12-29	Methods of treating psychological conditions
EP1267849B1 (en)	2005-02-16	Restricting reinstatement of drug use
US20060189599A1 (en)	2006-08-24	Treating alcohol and or substance abuse by antagonizing alpha 2 adrenergic receptors with weak dopamine blocking
US20020137767A1 (en)	2002-09-26	Methods for treating addictive disorders
KR100491027B1 (ko)	2005-09-30	물질남용질환치료를위한피리딜-및피리미딜-피페라진
TW574037B (en)	2004-02-01	Nicotine addiction treatment
MXPA98009265A (en)	1999-07-06	Piridil- and pyrimidil-piperazines in the treatment of disorders from the abuse of sustain